• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
SMA Community Priorities for Future Drug Therapies: Cross-Sectional Survey Findings Representing 410 Adults with SMA.脊髓性肌萎缩症患者群体对未来药物治疗的优先需求:涵盖410名脊髓性肌萎缩症成年患者的横断面调查结果
Neurol Ther. 2025 Jun;14(3):1083-1092. doi: 10.1007/s40120-025-00753-7. Epub 2025 May 3.
2
Spinal muscular atrophy: survival pattern and functional status.脊髓性肌萎缩症:生存模式与功能状态
Pediatrics. 2004 Nov;114(5):e548-53. doi: 10.1542/peds.2004-0668. Epub 2004 Oct 18.
3
Spinal Muscular Atrophy脊髓性肌萎缩症
4
"Getting ready for the adult world": how adults with spinal muscular atrophy perceive and experience healthcare, transition and well-being.“为成人世界做准备”:患有脊髓性肌萎缩症的成年人如何看待和体验医疗保健、过渡和幸福感。
Orphanet J Rare Dis. 2019 Apr 2;14(1):74. doi: 10.1186/s13023-019-1052-2.
5
Effectiveness of Nusinersen in Adolescents and Adults with Spinal Muscular Atrophy: Systematic Review and Meta-analysis.诺西那生钠治疗青少年和成人脊髓性肌萎缩症的有效性:系统评价与荟萃分析
Neurol Ther. 2024 Oct;13(5):1483-1504. doi: 10.1007/s40120-024-00653-2. Epub 2024 Sep 2.
6
Evaluating Benefit-risk Decision-making in Spinal Muscular Atrophy: A First-ever Study to Assess Risk Tolerance in the SMA Patient Community.评估脊髓性肌萎缩症的获益-风险决策:首次评估 SMA 患者群体风险承受能力的研究。
Clin Ther. 2019 May;41(5):943-960.e4. doi: 10.1016/j.clinthera.2019.03.012. Epub 2019 May 3.
7
A contemporary analysis of the Australian clinical and genetic landscape of spinal muscular atrophy: a registry based study.澳大利亚脊髓性肌萎缩症临床与基因状况的当代分析:一项基于登记处的研究
Lancet Reg Health West Pac. 2024 Nov 6;53:101237. doi: 10.1016/j.lanwpc.2024.101237. eCollection 2024 Dec.
8
Patient and Caregiver Outcomes After Onasemnogene Abeparvovec Treatment: Findings from the Cure SMA 2021 Membership Survey.患者和照护者结局在onasemnogene abeparvovec 治疗后:来自 Cure SMA 2021 会员调查的发现。
Adv Ther. 2023 Dec;40(12):5315-5337. doi: 10.1007/s12325-023-02685-w. Epub 2023 Sep 30.
9
The Cure SMA Clinical Trial Experience Survey: A Study of Trial Participant Perspectives on Clinical Trial Management and Patient-Centric Management Practices.脊髓性肌萎缩症治疗临床试验经验调查:一项关于试验参与者对临床试验管理和以患者为中心管理实践观点的研究。
Neurol Ther. 2022 Sep;11(3):1167-1181. doi: 10.1007/s40120-022-00360-w. Epub 2022 May 30.
10
Quality of life data for individuals affected by spinal muscular atrophy: a baseline dataset from the Cure SMA Community Update Survey.脊髓性肌萎缩症患者的生活质量数据:来自 Cure SMA 社区更新调查的基线数据集。
Orphanet J Rare Dis. 2020 Aug 24;15(1):217. doi: 10.1186/s13023-020-01498-2.

本文引用的文献

1
Challenges and opportunities in spinal muscular atrophy therapeutics.脊髓性肌萎缩症治疗的挑战与机遇。
Lancet Neurol. 2024 Feb;23(2):205-218. doi: 10.1016/S1474-4422(23)00419-2.
2
Psychometric evaluation of modified spinal muscular atrophy functional rating scale (SMAFRS) in adult patients using Rasch analysis.Rasch 分析评估改良型脊髓性肌萎缩症功能评分量表(SMAFRS)在成年患者中的应用。
Muscle Nerve. 2023 Mar;67(3):239-243. doi: 10.1002/mus.27785. Epub 2023 Jan 15.
3
Advances and limitations for the treatment of spinal muscular atrophy.脊髓性肌萎缩症治疗的进展与局限。
BMC Pediatr. 2022 Nov 3;22(1):632. doi: 10.1186/s12887-022-03671-x.
4
Management of Spinal Muscular Atrophy in the Adult Population.成人脊髓性肌萎缩症的管理。
Muscle Nerve. 2022 May;65(5):498-507. doi: 10.1002/mus.27519. Epub 2022 Feb 26.
5
Development of the SMA independence scale-upper limb module (SMAIS-ULM): A novel scale for individuals with Type 2 and non-ambulant Type 3 SMA.脊髓性肌萎缩症独立性量表上肢模块(SMAIS-ULM)的开发:一种针对2型和非行走型3型脊髓性肌萎缩症患者的新型量表。
J Neurol Sci. 2022 Jan 15;432:120059. doi: 10.1016/j.jns.2021.120059. Epub 2021 Nov 25.
6
The Cure SMA Membership Surveys: Highlights of Key Demographic and Clinical Characteristics of Individuals with Spinal Muscular Atrophy.《Cure SMA 会员调查》:脊髓性肌萎缩症个体关键人口统计学和临床特征要点。
J Neuromuscul Dis. 2021;8(1):109-123. doi: 10.3233/JND-200563.
7
Health, wellbeing and lived experiences of adults with SMA: a scoping systematic review.成人大 SMA 患者的健康、福利和生活体验:范围系统综述。
Orphanet J Rare Dis. 2020 Mar 12;15(1):70. doi: 10.1186/s13023-020-1339-3.
8
Patient Reported Impact of Symptoms in Spinal Muscular Atrophy (PRISM-SMA).脊髓性肌萎缩症患者症状影响报告(PRISM-SMA)。
Neurology. 2018 Sep 25;91(13):e1206-e1214. doi: 10.1212/WNL.0000000000006241. Epub 2018 Aug 24.
9
Prevalence, incidence and carrier frequency of 5q-linked spinal muscular atrophy - a literature review.5号染色体连锁型脊髓性肌萎缩症的患病率、发病率及携带者频率——文献综述
Orphanet J Rare Dis. 2017 Jul 4;12(1):124. doi: 10.1186/s13023-017-0671-8.

脊髓性肌萎缩症患者群体对未来药物治疗的优先需求:涵盖410名脊髓性肌萎缩症成年患者的横断面调查结果

SMA Community Priorities for Future Drug Therapies: Cross-Sectional Survey Findings Representing 410 Adults with SMA.

作者信息

Peterson Ilse S, Chitale Ramaa, Curry Mary A, Belter Lisa T

机构信息

Faegre Drinker Consulting, Washington, DC, USA.

Contractor to Faegre Drinker Consulting, Washington, DC, USA.

出版信息

Neurol Ther. 2025 Jun;14(3):1083-1092. doi: 10.1007/s40120-025-00753-7. Epub 2025 May 3.

DOI:10.1007/s40120-025-00753-7
PMID:40317455
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12089628/
Abstract

INTRODUCTION

Despite advances in the therapeutic landscape for spinal muscular atrophy (SMA), unmet needs for those with this condition persist. This study seeks to characterize unmet needs that adults with SMA hope future therapies will address and explores associations between reported needs and health status and demographic characteristics.

METHODS

Close-ended questions from 2021 to 2023 Cure SMA Community Update Survey data were used to assess the importance of needs related to muscle and motor function, lung function and bulbar function, and general functioning. Data was stratified by SMA type and mobility status, and Fisher's exact tests were used to assess for statistically significant differences based on these characteristics. Variations in reported needs were further explored with regressions controlling for sex, education, maximum mobility, and drug treatment status.

RESULTS

The sample included 410 adults who answered questions on unmet needs. Most had type 2 or type 3 SMA (48% and 45%, respectively). Gaining muscle strength was the most frequently reported unmet need, and followed by improving daily functioning, achieving new motor function, and stabilizing motor function. Stratifications and regressions identified statistically significant differences in treatment needs based on health status and demographic characteristics (p < 0.05). Most notably, people with more severe types of SMA and lower mobility were more likely to report items related to lung function and bulbar function as important.

CONCLUSION

This research highlights treatment priorities for adults with SMA.

摘要

引言

尽管脊髓性肌萎缩症(SMA)的治疗领域取得了进展,但患有这种疾病的患者仍存在未满足的需求。本研究旨在描述成年SMA患者希望未来治疗能够解决的未满足需求,并探讨报告的需求与健康状况和人口统计学特征之间的关联。

方法

使用2021年至2023年治愈SMA社区最新调查数据中的封闭式问题,评估与肌肉和运动功能、肺功能和延髓功能以及总体功能相关需求的重要性。数据按SMA类型和活动状态分层,并使用Fisher精确检验评估基于这些特征的统计学显著差异。通过控制性别、教育程度、最大活动能力和药物治疗状态的回归分析,进一步探讨报告需求的差异。

结果

样本包括410名回答了未满足需求问题的成年人。大多数人患有2型或3型SMA(分别为48%和45%)。增强肌肉力量是最常报告的未满足需求,其次是改善日常功能、获得新的运动功能和稳定运动功能。分层和回归分析确定了基于健康状况和人口统计学特征的治疗需求存在统计学显著差异(p<0.05)。最值得注意的是,SMA类型更严重且活动能力较低的人更有可能报告与肺功能和延髓功能相关的项目很重要。

结论

本研究突出了成年SMA患者的治疗重点。